OACCU Oaktree Acquisition Corp. III Life Sciences: institutional ownership and insider trading
6 funds reported holding $9.47M of Oaktree Acquisition Corp. III Life Sciences in their latest 13F filings; in Q2 2026 funds net sold $496K, with 0 new positions and 1 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
OACCU revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $1.60M
- Quarter ended Mar 31, 2026: revenue n/a, net income $1.39M
- Quarter ended Dec 31, 2025: revenue n/a, net income $1.79M
- Quarter ended Sep 30, 2025: revenue n/a, net income $1.97M
Largest institutional holders of OACCU
- ADAR1 Capital Management, LLC — $5.60M
- Affinity Asset Advisors, LLC — $2.75M
- Athos Capital Ltd — $550K
- Clear Street Group Inc. — $242K
- CLEAR STREET LLC — $221K
- UBS Group AG (UBS) — $104K
5%+ owners
- Oaktree Acquisition Holdings III LS, LLC: 22.3% (Schedule 13G, filed Feb 12, 2025)
- AQR Capital Management, LLC: 7.3% (Schedule 13G/A, filed May 14, 2025)
- Barclays PLC: 7.0% (Schedule 13G, filed Aug 13, 2026)
- THE GOLDMAN SACHS GROUP, INC.: 6.2% (Schedule 13G, filed May 11, 2026)
- Decagon Asset Management LLP: 5.5% (Schedule 13G, filed Aug 14, 2026)
- Fort Baker Capital Management LP: 5.1% (Schedule 13G, filed May 15, 2026)
Who owns the most OACCU stock?
The largest institutional holders of Oaktree Acquisition Corp. III Life Sciences in the latest 13F filings are ADAR1 Capital Management, LLC ($5.60M), Affinity Asset Advisors, LLC ($2.75M), Athos Capital Ltd ($550K).
Are insiders buying or selling OACCU?
No open-market insider buys or sells of Oaktree Acquisition Corp. III Life Sciences were reported in the last 12 months.